Table 1.

Clinical trials using ivermectin for controlling malaria transmission

ID number	Status	Study	Condition	Interventions	Outcomes: Primary (secondary)	Reference
NCT02511353 (ClinicalTrials.gov)	Recruiting	Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study	Malaria	Drug (3-day course): dihydroartemisinin-piperaquine+placebo; dihydroartemisinin-piperaquine+ivermectin (300 μg/kg/day) ; dihydroartemisinin-piperaquine+ivermectin (600 μg/kg/day))	Mosquito survival (Number of clinical malaria cases, AUC and Cmax for ivermectin and piperaquine, Hb concentration, Safety)	no
NCT02509481 (ClinicalTrials.gov)	Active, not recruiting	Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study	Malaria, Lymphatic Filariasis	Drug: Ivermectin+Albendazole (1×); Ivermectin+Albendazole (1×) + repeated ivermectin (5× at 3 weeks interval)	Incidence of clinical malaria episodes (Force of infection, Soil-transmitted helminths, EIR, Safety)	no
NCT01603251 (ClinicalTrials.gov)	Completed	Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission	Malaria	Drug: Artemether-lumefantrine combination (3-day course, twice a day) + placebo (1st and 5th dose of AL); Artemether-lumefantrine combination + single dose Ivermectin (200 μg/kg with 1st dose of AL, placebo with 5th dose of AL); Artemether-lumefantrine combination + repeated dose Ivermectin (200 μg/kg with 1st and 5th doses of AL)	Safety (Mosquitocidal activity)	[11]

Search in ClinicalTrials.gov, EU Clinical Trials Register, ISRCTN Registry, Google, Pubmed, Web of Sciences® with keywords: ivermectin + malaria + clinical trial